Navigation Links
Savara Pharmaceuticals Announces FDA Grant of Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Its Lead Product, AeroVanc
Date:12/10/2013

AUSTIN, Texas, Dec. 10, 2013 /PRNewswire/ -- Savara Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has designated the Company's lead antibiotic product, AeroVanc, as a Qualified Infectious Disease Product (QIDP) for the treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis patients. The company also received Fast Track designation for AeroVanc pursuant to section 506(a)(1) of the Food and Drug Administration Safety and Innovation Act (FDASIA).

The QIDP and Fast Track designation provide AeroVanc access to certain incentives, including priority review associated with a New Drug Application (NDA) submission and an additional five years of exclusivity under the Hatch-Waxman Act upon FDA approval of AeroVanc. Last year AeroVanc received orphan designation, which provides the product seven years of market exclusivity, and various other incentives. 

"The recent QIDP status forms an important part of our market exclusivity strategy," says Rob Neville, CEO of Savara Pharmaceuticals. "This designation along with Orphan Drug status, our formulation patent protection and our inhalation device exclusivity creates a very robust protection from competition."

Savara Pharmaceuticals is currently conducting a nationwide Phase II clinical trial evaluating the safety and efficacy of AeroVanc in CF patients. For more information, please visit http://www.aerovanc.com.  

About AeroVanc
Vancomycin is an FDA-approved intravenously administered antibiotic with proven efficacy in the treatment of MRSA infections. AeroVanc is an investigational, proprietary inhaled dry powder form of vancomycin in a capsule-based device designed for convenient self-administration. AeroVanc is currently being developed as a treatment for persistent MRSA lung infection in CF patients. B
'/>"/>

SOURCE Savara Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savara Pharmaceuticals Appoints Two New Members to Its Board of Directors
2. Savara Pharmaceuticals Initiates Phase 2 Clinical Trial of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients
3. Tech Coast Angels Contributes More Than $3 Million to $16 Million Savara Pharmaceuticals Series B
4. Savara Pharmaceuticals Announces Formation of Clinical Advisory Board
5. Savara Pharmaceuticals AeroVanc Granted U.S. Orphan Drug Designation for the Treatment of MRSA Lung Infection in Cystic Fibrosis Patients
6. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
7. Actinium Pharmaceuticals to Present at the 24th Annual Oppenheimer Healthcare Conference
8. Neuraltus Pharmaceuticals NP001 Phase 2 Results Highlighted at the 24th International Symposium on ALS/MND
9. Imprimis Pharmaceuticals Announces Plans to Pursue Compounding Pharmacy Strategy in Accordance with the Recently Passed Drug Quality and Security Act
10. Actinium Pharmaceuticals Announces Clinical Advisory Board Meeting At The 2013 ASH Conference
11. Questcor Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... 17, 2014 ... announced the addition of the  "China Interventional ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... China impacted by ... consumption concept, dietary habit, way of working ...
(Date:10/17/2014)... , October 17, 2014 ... Pharmaceuticals Inc. (NASDAQ: ARNA ), NPS Pharmaceuticals ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: ... CPRX). Free research on these five companies can be ... markets on Thursday, October 16, 2014, ended on a ...
(Date:10/17/2014)... , Oct. 17, 2014  Ameritox SM , the ... appointment of Thomas Smith , M.D., as Chief ... field-based team offering scientific resources for healthcare providers, patients ... held leadership positions at a variety of healthcare companies ... both the pain and behavioral health sides of Ameritox,s ...
Breaking Medicine Technology:China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Ameritox Appoints New Chief Medical Officer 2
... 5 Lincare Holdings Inc. (Nasdaq: LNCR ) ... the employment agreements with its Chief Executive Officer, John ... S. Schabel and its Chief Financial Officer, Paul G. ... each executive officer,s employment with the company for three ...
... CHENGDU, China, Oct. 5 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical ... manufacturer and,supplier of modernized traditional Chinese medicine ("TCM") and ... to be paid,to its common stock shareholders. The dividend ... of October 30, 2009, with the actual distribution,occurring on ...
Cached Medicine Technology:Lincare Holdings Inc. Extends Terms of Employment Agreements with Executive Officers 2Tianyin Pharmaceutical, Co. Announces Cash Dividend to Common Shareholders - Record Date October 30, 2009 2
(Date:10/20/2014)... Rockynol Retirement Community broke ground on ... $11 million project will include the latest in Assisted ... full-service restaurant style dining. , “We are excited to ... Living apartments,” said Kara Hanzie, Rockynol Executive Director during ... care and this investment is proof of our commitment.” ...
(Date:10/20/2014)... Cleveland, Ohio (PRWEB) October 20, 2014 Unveiled ... Affairs’ new Strategic Direction Scorecard conservatively estimates member hospital ROI ... dollar spent on dues, The Center provides $12.50 in value ... ROI is (Member Value – Member Dues)/Member Dues. , ... get at this number and we think the methodology is ...
(Date:10/19/2014)... Hastings and Hastings, a Phoenix personal injury law ... greater Phoenix area and across Arizona reports record demand ... automobile accidents. Statistics have indicated a steady increase in ... such, Hastings and Hastings has seen a steady increase ... have been injured through no fault of their own ...
(Date:10/19/2014)... working in the garment industry for decades, LunaDress’ dress specialists ... one of the company’s top designers, many ladies like prom ... add beauty to them. Chiffon floor length outfits are also ... selection of 2014 long prom dresses. , As a ... in over 20 popular designs. The company intends to meet ...
(Date:10/19/2014)... Stephen T. Greenberg, M.D., with offices in Woodbury, Southampton and ... as one of Long Island’s best cosmetic surgeons. In ... the best provider for Botox injections. Glisten, his Skin & ... best Laser Treatment center on Long Island.* , The voting ... the contest once per day, per IP address. , Stephen ...
Breaking Medicine News(10 mins):Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Dr. Stephen T. Greenberg – Nominated for the 10th Consecutive Year for One of Long Island’s Best Cosmetic Surgeons for 2015 by the Long Island Press 2
... The medical community has repeatedly warned against plying young children with ... parents seem to care . Certainly not in Australia. ... extractions, dentists in that country say. ,In the ... but to remove all 20 baby teeth. ,"It's ...
... long ago there was a theory doing the rounds that ... autistic individual. This theory was not well received and ... prompted the proponents of the theory to associate the schemingly ... autism? ,Autism is a developmental disability that affects ...
... way for 70-year-old Hakimuddin of Orissa and his three ... after the impoverished man wrote to India's president ... district collector of Bhadrak in Orissa constituted a team ... on the condition of the poor family in Kamalpur ...
... common genetic variation on chromosome 9p21 is linked to a ... new international research study . The findings are published today ... an upcoming printed edition of the journal. ,Researchers ... of suffering a heart attack (myocardial infarction) and a 2.02-fold ...
... (CE-US) after a liver transplant is highly accurate in ... to a recent study. ,The study consisted ... exam after developing fluid in the abdomen and/or unclear ... serious complication in the early post transplant period, caused ...
... University researchers seem to know what makes certain babies prone ... Edinburgh University and the Royal Hospital for Sick Children in ... premature and small babies which expose them to risks of ... of the maternal and child health sciences division, are team ...
Cached Medicine News:Health News:Experts Call for Warning Lables on Fruit Juice to Save Kids' Teeth 2Health News:Diet for Autism 2Health News:Diet for Autism 3Health News:Disabled Orissa Brothers Lives Saved by Timely Intervention 2Health News:Genetic Variation is Linked to Substantial Risk in Heart Attack 2
... to 350 Liters of pure water, Complete, ... of Purified Water,Millipores compact S.D.S. Storage and ... to 350 liters of purified water produced ... maintain consistent purity of stored water, provide ...
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
... Millipore has developed a range ... to match specific water quality requirements. ... systems is designed to specifically target ... as HPLC, molecular biology and ICP-MS. ...
Medicine Products: